GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Approval for dMMR Endometrial Cancer

 GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Approval for dMMR Endometrial Cancer

GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Approval for dMMR Endometrial Cancer

Shots:

  • The US FDA has approved the BLA filing for Jemperli for adult patients with dMMR recurrent or advanced solid tumors endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a Pt.-containing regimen
  • AnaptysBio has received $20M as milestones upon the FDA’s approval and will receive $45M as regulatory milestones in the US & EU, $165M as sales milestones following achievement of annual sales revenues with royalties range from 8% to 25% of global sales
  • Jemperli is currently being evaluated in P-III trials for recurrent or primary advanced EC and stage III or IV non-mucinous epithelial ovarian cancer and is the first AnaptysBio-generated Ab out of 8 to obtain FDA approval

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post